- Language: English
- 774 Pages
- Published: October 2012
- Region: Global
Unigene Laboratories, Inc.
- Published: February 2013
- Region: Global
- 1 pages
- Sheila Greco Associates
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. ForticalR, Unigene`s nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for ForticalR to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene`s patented oral delivery technology has successfully delivered, in preclinical andor clinical trials, various peptides including calcitonin, PTH and insulin. Unigene`s patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call 973 265-1100 or visit www.unigene.com.
These individual Business Lists are 100% staff verified and details the company’s roster of key professionals and key decision makers.
- In addition to the executive contacts, this report contains:
- Global HQ Location
- US Address (Street, City, State & Zip)
- US HQ Phone Number & Company Website Address
- Most Recent
- Revenues Reported,
- Number of Employees and Industry.
These Business Lists do not include direct-dial phone numbers for all executives listed.
- This will provide the direct phone number.
- This report provides the HQ phone number and the accurate executive name and title.